Clinical Trials Browser

Lymphoma, Large B-Cell, Diffuse × Lisaftoclax × 30 days × Clear all

NCT07601607 2026-05-22

Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1/2 Not yet recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse